Nestlé already profits from selling us foods that make us sick. Now it wants to profit from selling us the remedies for those sicknesses too.
The world’s biggest food company is getting worried. Its $240 billion empire is built on peddling sugar. But now public opinion is turning against the sweet stuff and confectionery sales are falling.
So Nestlé is planning to start selling us medicines for diabetes and heart conditions alongside the sugar-laden snacks. Seriously.
It’s a staggeringly cynical move -- and a huge conflict of interest. Will you join us on calling Nestlé out on its plans?
Nestlé: if you want to fix the world’s health problems, stop selling bad food.
Nestlé is the world’s biggest food company. It sells its products in almost every country on Earth. It has a workforce of one-third of a million people. And at the heart of its empire is the selling of sugar-laden foods -- from chocolates and sweets to ice creams and sugary drinks.
But the company’s confectionery sales have fallen every year since 2012, as the health impacts of sugar become more widely known. Pharmaceuticals, on the other hand, are thriving. So Nestlé wants to rebrand itself as a “nutrition, health and wellness company” -- by inventing and selling drugs for everything from chronic illnesses to aging, while keeping its core food business.
The hypocrisy is astonishing -- and we can’t let Nestlé get away with it.
We know Nestlé doesn’t care about ethics. This is the corporation that poisoned its milk with melamine, purchases cocoa from plantations that use child slave labor, and launched a breast milk substitute campaign in the 1970s that contributed to the suffering and deaths of thousands of babies from poor communities.
But we also know that Nestlé is sensitive to public outcry, and that it's been beaten before. Let’s put pressure on Nestlé to take real action to protect public health.
Let’s tell Nestlé to sort out the sugar content of its products instead of trying to profit from bad food, and then profit from the remedy.
More information
Bloomberg. 5 May 2016.